Obesity, GLP-1 Treatment, and Public Perception in the UK
The Promise of the Pill: Attitudes Towards GLP-1 Treatment and New Formats in the UK
In anticipation of new GLP-1 formats launching in the UK, combining a nationally representative survey of 2,000 UK adults with insights from 3,488 current GLP-1 patients.
Summary
GLP-1 treatments are changing the way obesity is treated in the UK. But as new oral tablet versions begin to emerge, the conversation is shifting again. The question is no longer simply whether these treatments work. Increasingly, people are asking what kind of treatment they would feel comfortable using, and under what conditions.
To explore this changing landscape, Simple Online Healthcare commissioned new research examining public attitudes towards pill-based GLP-1 treatments compared with injections. The findings combine a nationally representative survey of 2,000 UK adults with responses from 3,488 current GLP-1 patients.
The research reveals strong initial interest in pill-based treatments, particularly among people who are not currently using GLP-1 medication. Tablets are seen as more familiar, less invasive and easier to fit into everyday life.
However, the findings also show that convenience alone is not enough. Once people receive more information about daily dosing requirements, side effects and effectiveness trade-offs, enthusiasm drops significantly.
Finding 1: Awareness Is Growing – But Understanding and Consideration Still Lag
Public familiarity with GLP-1 treatments is increasing, but awareness remains uneven across the UK population and does not necessarily translate into treatment consideration.
Only 40% of UK adults say they are familiar with GLP-1 treatments. Familiarity is highest among younger and mid-life adults, but drops sharply among older age groups, despite older adults often carrying a greater burden of obesity-related disease.
Even where awareness exists, most people are still reluctant to consider treatment. More than three quarters of non-users say they are unlikely to consider GLP-1 medication for weight loss.
The findings suggest that public perceptions of obesity continue to shape attitudes towards treatment. Around 30% of UK adults still view obesity primarily as a lifestyle issue, while only a small minority — just 14% — see GLP-1 use as a legitimate medical treatment.
This framing shapes who feels eligible to seek help and how openly people discuss their options.
Finding 2: Pills Increase Interest – But Not Automatic Uptake
A daily pill format has strong initial appeal, especially among people who are not currently using GLP-1 medication. 61% of non-users say they would prefer a daily tablet compared with just 9% who would choose a weekly injection.
The most commonly perceived benefits are avoiding injections, convenience and ease of use. Nearly seven in ten believe a pill would fit more easily into everyday routines.
However, preference does not automatically translate into action. Only 31% say a pill would make them more likely to consider GLP-1 treatment overall. Among people already trying to lose weight, this rises to 42%.
This suggests oral treatments may widen interest in the category, particularly among those who previously felt uncomfortable with injections, but are unlikely to transform uptake on their own.
Finding 3: Uncertainty Remains One of the Biggest Barriers
While awareness of GLP-1 treatments is growing, public understanding remains limited.
Many respondents reported uncertainty around how pill-based GLP-1s would compare with injections in practice, particularly around effectiveness, side effects and long-term outcomes.
Nearly half of non-users say they are unsure how effective a pill would be compared with injectable treatments, while more than half are uncertain about side effects.
This uncertainty remains consistent across age groups and levels of weight-loss engagement, suggesting that education and expectation-setting will play a critical role as new treatment formats become available.
Finding 4: Existing Patients Assess Pills Differently
For people already using GLP-1 treatments, attitudes towards pills are shaped less by novelty and more by practical trade-offs. Current patients are more focused on questions of effectiveness, value and convenience in day-to-day life.
The strongest perceived advantages among patients are lower cost and easier travel or storage. However, many also express concerns about whether oral treatments would deliver similar results to injectable medication.
Around 88% of patients say they would only switch if pills were as effective as, or more effective than, injections. Price also matters. Six in ten say they would only switch if oral treatments were at least 20% cheaper.
Finding 5: More Information Changes Perception
One of the most revealing findings in the study came after respondents were given additional information about pill-based GLP-1 treatments. Participants were informed that pills may require strict daily timing, need to be taken before food, and could potentially be less effective than injections.
Following this information, preference for pills fell sharply among both non-users and existing patients.
This suggests that much of the early enthusiasm for tablets is driven by assumptions about simplicity and convenience. Once people understand the realities of treatment, decision-making becomes more cautious and more clinically focused.
Importantly, this does not suggest rejection. Instead, it points to patients making increasingly informed and rational healthcare decisions.
Finding 6: Stigma Still Shapes Treatment Decisions
The research also highlights the continuing role of stigma in obesity treatment.
Previous Simple Online Healthcare research found that two-thirds of patients hide their treatment from some or all friends and family. In this study, 41% of current patients believe a pill format could reduce feelings of judgement.
Because tablets are more familiar and less visible than injections, some respondents felt they may normalise treatment or make it easier to discuss.
Why It Matters
Oral GLP-1 treatments could play an important role in widening access to obesity care, particularly for people who feel uncomfortable with injections or who have delayed treatment because of stigma, privacy concerns or practical barriers.
But the research also shows that innovation alone is not enough.
Improving long-term obesity outcomes will depend not just on new medicines, but on better public understanding of obesity as a chronic condition, clearer expectations around treatment, and care pathways that combine medication with behavioural and clinical support.
Without that shift, awareness may continue to rise faster than understanding, leaving many clinically eligible people uncertain about whether treatment is right for them.